Targeted Toxicities: Protocols for Monitoring the Adverse Events of Targeted Therapies Used in the Treatment of Non-Small Cell Lung Cancer
Targeted therapies have revolutionized the treatment for many patients with non-small cell lung cancer (NSCLC). Multiple new oral targeted therapies have been approved in the last decade; however, their overall efficacy may be reduced by poor adherence, treatment interruptions, or dose reductions du...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-05-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/11/9429 |
| _version_ | 1797597391659991040 |
|---|---|
| author | Jacobi B. Hines Benjamin Bowar Emma Levine Alessandra Esposito Marina C. Garassino Christine M. Bestvina |
| author_facet | Jacobi B. Hines Benjamin Bowar Emma Levine Alessandra Esposito Marina C. Garassino Christine M. Bestvina |
| author_sort | Jacobi B. Hines |
| collection | DOAJ |
| description | Targeted therapies have revolutionized the treatment for many patients with non-small cell lung cancer (NSCLC). Multiple new oral targeted therapies have been approved in the last decade; however, their overall efficacy may be reduced by poor adherence, treatment interruptions, or dose reductions due to adverse events. Most institutions lack standard monitoring protocols for toxicities from these targeted agents. This review describes important adverse events observed in clinical trials and reported by the U.S. Food and Drug Administration for both currently approved and upcoming promising therapies in the treatment of NSCLC. These agents cause a range of toxicities, including dermatologic, gastroenteric, pulmonary, and cardiac toxicities. This review proposes protocols for routine monitoring of these adverse events, both prior to initiation of therapy and while on treatment. |
| first_indexed | 2024-03-11T03:05:34Z |
| format | Article |
| id | doaj.art-4edc3a1d8e8a4035a04b579c9e6030bb |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-11T03:05:34Z |
| publishDate | 2023-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-4edc3a1d8e8a4035a04b579c9e6030bb2023-11-18T07:58:53ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-05-012411942910.3390/ijms24119429Targeted Toxicities: Protocols for Monitoring the Adverse Events of Targeted Therapies Used in the Treatment of Non-Small Cell Lung CancerJacobi B. Hines0Benjamin Bowar1Emma Levine2Alessandra Esposito3Marina C. Garassino4Christine M. Bestvina5Department of Medicine, Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL 60637, USADepartment of Medicine, Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL 60637, USABooth School of Business, University of Chicago, Chicago, IL 60637, USADepartment of Medicine, Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL 60637, USADepartment of Medicine, Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL 60637, USADepartment of Medicine, Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL 60637, USATargeted therapies have revolutionized the treatment for many patients with non-small cell lung cancer (NSCLC). Multiple new oral targeted therapies have been approved in the last decade; however, their overall efficacy may be reduced by poor adherence, treatment interruptions, or dose reductions due to adverse events. Most institutions lack standard monitoring protocols for toxicities from these targeted agents. This review describes important adverse events observed in clinical trials and reported by the U.S. Food and Drug Administration for both currently approved and upcoming promising therapies in the treatment of NSCLC. These agents cause a range of toxicities, including dermatologic, gastroenteric, pulmonary, and cardiac toxicities. This review proposes protocols for routine monitoring of these adverse events, both prior to initiation of therapy and while on treatment.https://www.mdpi.com/1422-0067/24/11/9429non-small cell lung cancermolecular targeted therapiesadverse drug eventstoxicitypharmacovigilance |
| spellingShingle | Jacobi B. Hines Benjamin Bowar Emma Levine Alessandra Esposito Marina C. Garassino Christine M. Bestvina Targeted Toxicities: Protocols for Monitoring the Adverse Events of Targeted Therapies Used in the Treatment of Non-Small Cell Lung Cancer International Journal of Molecular Sciences non-small cell lung cancer molecular targeted therapies adverse drug events toxicity pharmacovigilance |
| title | Targeted Toxicities: Protocols for Monitoring the Adverse Events of Targeted Therapies Used in the Treatment of Non-Small Cell Lung Cancer |
| title_full | Targeted Toxicities: Protocols for Monitoring the Adverse Events of Targeted Therapies Used in the Treatment of Non-Small Cell Lung Cancer |
| title_fullStr | Targeted Toxicities: Protocols for Monitoring the Adverse Events of Targeted Therapies Used in the Treatment of Non-Small Cell Lung Cancer |
| title_full_unstemmed | Targeted Toxicities: Protocols for Monitoring the Adverse Events of Targeted Therapies Used in the Treatment of Non-Small Cell Lung Cancer |
| title_short | Targeted Toxicities: Protocols for Monitoring the Adverse Events of Targeted Therapies Used in the Treatment of Non-Small Cell Lung Cancer |
| title_sort | targeted toxicities protocols for monitoring the adverse events of targeted therapies used in the treatment of non small cell lung cancer |
| topic | non-small cell lung cancer molecular targeted therapies adverse drug events toxicity pharmacovigilance |
| url | https://www.mdpi.com/1422-0067/24/11/9429 |
| work_keys_str_mv | AT jacobibhines targetedtoxicitiesprotocolsformonitoringtheadverseeventsoftargetedtherapiesusedinthetreatmentofnonsmallcelllungcancer AT benjaminbowar targetedtoxicitiesprotocolsformonitoringtheadverseeventsoftargetedtherapiesusedinthetreatmentofnonsmallcelllungcancer AT emmalevine targetedtoxicitiesprotocolsformonitoringtheadverseeventsoftargetedtherapiesusedinthetreatmentofnonsmallcelllungcancer AT alessandraesposito targetedtoxicitiesprotocolsformonitoringtheadverseeventsoftargetedtherapiesusedinthetreatmentofnonsmallcelllungcancer AT marinacgarassino targetedtoxicitiesprotocolsformonitoringtheadverseeventsoftargetedtherapiesusedinthetreatmentofnonsmallcelllungcancer AT christinembestvina targetedtoxicitiesprotocolsformonitoringtheadverseeventsoftargetedtherapiesusedinthetreatmentofnonsmallcelllungcancer |